June 2019 - Volume 3 - Issue - Contributor Index

Author:
B., R.

LONG TERM FOLLOW-UP OF MAINTENANCE THERAPY WITH INTEREFRON ALPHA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA PATIENTS-SINGLE CENTER EXPERIENCE: PB2175

Batinic, J.; Bašic-Kinda, S.; Pulanic, D.; More

HemaSphere. 3:976, June 2019.

Author:
Babaeva, F.
Author:
Babaeva, T.
Author:
Babaoglu, K.
Author:
Babenko, E.
Author:
Babiker, H.
Author:
Babon, J. J.
Author:
BABU, G.
Author:
Baccarani, M.

SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED: S123

Mancini, M.; De Santis, S.; Monaldi, C.; More

HemaSphere. 3:13-14, June 2019.

OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY: S882

Malagola, M.; Efficace, F.; Polverelli, N.; More

HemaSphere. 3:396-397, June 2019.

Author:
Baccini, V.
Author:
Bacher, V. U.
Author:
Bachier, C. R.
Author:
Bachir, J.
Author:
Bachy, E.

REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM: S1600

Thieblemont, C.; Legouill, S.; Di Blasi, R.; More

HemaSphere. 3:736-737, June 2019.

Author:
Bacigalupo, A.
Author:
Backs, J.
Author:
Baclig, N. V.

SAFETY AND RESOURCE UTILIZATION FOLLOWING EARLY HOSPITAL DISCHARGE AFTER INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA (AML): A 4-YEAR RETROSPECTIVE ANALYSIS: PF253

Howard, N. P.; Halpern, A. B.; Othus, M.; More

HemaSphere. 3:78, June 2019.

Author:
Bacon, P.

HARMONY ALLIANCE: EUROPEAN PUBLIC-PRIVATE DATA COLLECTION LEADS THE WAY - FIRST RESULTS OF THE “PROOF-OF-PRINCIPLE” STUDY IN ACUTE MYELOID LEUKEMIA: PS1003

Bullinger, L.; Valk, P.; Versluis, J.; More

HemaSphere. 3:451, June 2019.

POMALIDOMIDE-BASED TREATMENT IN RELAPSED REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF BASELINE CHARACTERISTICS AND SAFETY PROFILE OF PATIENTS WHO DIED IN THE EUROPEAN POST APPROVAL SAFETY STUDY: PS1418

Gamberi, B.; Abildgaard, N.; Payer, Ramirez A.; More

HemaSphere. 3:652, June 2019.

POMALIDOMIDE PLUS LOW-DEXAMETHASONE TREATMENT FOR ≥ 1 YEAR IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A SUBANALYSIS OF THE MM-013 PHASE 2 STUDY: PB2117

Weisel, K.; Dimopoulos, M.; Cook, M.; More

HemaSphere. 3:953, June 2019.

Author:
Bacovsky, J.
Author:
Baculea, S.
Author:
badarkhe, G.
Author:
Badawy, R.
Author:
Badazhapova, D.
Author:
Badell, I.
Author:
Badens, C.
Author:
Bader, P.

TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH-RISK CYTOGENETIC ABNORMALITIES: S1618

Grupp, S.; Maude, S.; Baruchel, A.; More

HemaSphere. 3:746-747, June 2019.

Author:
Badiali, L.

DEVELOPMENT AND OPTIMISATION OF A FULLY HUMAN FVIII MIMETIC BISPECIFIC ANTIBODY FOR PATIENTS WITH HAEMOPHILIA A: PF338

Wang, W.; Blackwood, J.; Magliozzi, R.; More

HemaSphere. 3:120-121, June 2019.

Author:
Badiola, J.

SAFETY AND EFFECTIVENESS OF CHLORAMBUCIL-OBINUTUZUMAB IN THE FRONT LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: REAL-LIFE DATA FROM ANDALUSIAN LYMPHOID NEOPLASM GROUP (GRANEL): PB1898

Puerta, Puerta J.M.; Palanco, Martín V.; Badiola, J.; More

HemaSphere. 3:865, June 2019.

PERCEPTION OF THE DISCONTINUATION OF TYROSINE-KINASE INHIBITOR TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA OF THE ANDALUSIAN GROUP OF CML (GALMC): PB2267

Fernandez, E. López; Puerta, Puerta J. M.; Badiola, J.; More

HemaSphere. 3:1013-1014, June 2019.

Author:
Badman, J.
Author:
Bae, S. H.
Author:
Baech, J.

OSTEOPOROSIS AND LOW-ENERGY FRACTURES AFTER TREATMENT FOR LYMPHOMA WITH CORTICOSTEROID-CONTAINING IMMUNOCHEMOTHERAPY: A DANISH NATIONWIDE COHORT STUDY: PF304

Baech, J.; Hansen, S. M.; Øvlisen, A. K.; More

HemaSphere. 3:104, June 2019.

Author:
Baek, D. W.
Author:
Baek, H. J.
Author:
Baer, C.

INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: PF532

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3:218-219, June 2019.

Author:
Baer, M.

FT-2102, AN IDH1 M INHIBITOR, COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS): RESULTS FROM A PHASE 1 STUDY: PF269

Cortes, J. E.; Watts, J.; Baer, M.; More

HemaSphere. 3:86-87, June 2019.

GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL TRIAL: S876

Perl, A.; Martinelli, G.; Cortes, J.; More

HemaSphere. 3:392-393, June 2019.

FT-2102, AN IDH1 M INHIBITOR, INDUCES MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) TREATED IN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY: PS1051

De Botton, S.; Watts, J.; Baer, M.; More

HemaSphere. 3:475-476, June 2019.

Author:
Baer, M. R.

KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: END OF PHASE 1 RESULTS OF ZUMA-3: PS945

Shah, B. D.; Bishop, M. R.; Oluwole, O. O.; More

HemaSphere. 3:426, June 2019.

Author:
Baffert, S.
Author:
Bagger, F. O.

GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA: S113

Fagnan, A.; Piqué Borràs, Riera M.; Ignacimouttou, C.; More

HemaSphere. 3:8-9, June 2019.

Author:
Bagguley, T.

TRANSFUSION DEPENDENCY IS ASSOCIATED WITH PRESENCE OF TOXIC IRON SPECIES AND INFERIOR SURVIVAL IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES: S838

Hoeks, M.; Bagguley, T.; Roelofs, R.; More

HemaSphere. 3:373, June 2019.

Author:
Bagnoli, J. W.
Author:
Bagot, C.

SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY: PF691

Todd, S.; Infirri, Sardo S.; Miah, H.; More

HemaSphere. 3:299-300, June 2019.

Author:
Bagot, M.
Author:
Bahadir, A.
Author:
Bahceci, E.

GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL TRIAL: S876

Perl, A.; Martinelli, G.; Cortes, J.; More

HemaSphere. 3:392-393, June 2019.

OPEN-LABEL STUDY OF GILTERITINIB, GILTERITINIB PLUS AZACITIDINE, OR AZACITIDINE ALONE IN NEWLY DIAGNOSED FLT3-MUTATED AML PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: RESULTS FROM THE SAFETY COHORT: PS1065

Esteve, J.; Schots, R.; Del Castillo, Bernal T.; More

HemaSphere. 3:482, June 2019.

Author:
Bahlis, N.

SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: PF587

Chen, C.; Gasparetto, C.; White, D.; More

HemaSphere. 3:245, June 2019.

IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA: PF592

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3:248-249, June 2019.

RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA: S823

Mateos, M.-V.; Nahi, H.; Legiec, W.; More

HemaSphere. 3:364, June 2019.

A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PS1414

Gasparetto, C.; Lentzsch, S.; Schiller, G.; More

HemaSphere. 3:650, June 2019.

SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS: S1606

Gasparetto, C.; Lentzsch, S.; Schiller, G.; More

HemaSphere. 3:740, June 2019.

Author:
Bahlis, N. J.

EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK: PF591

Dimopoulos, M. A.; San-Miguel, J.; White, D.; More

HemaSphere. 3:247-248, June 2019.

FASTER & SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D-RD) VS RD: MAIA: PF603

Perrot, A.; Facon, T.; Plesner, T.; More

HemaSphere. 3:255, June 2019.

HEALTH-RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT: PF631

Reece, D.; Bahlis, N. J.; Samaras, C.; More

HemaSphere. 3:268-269, June 2019.

Author:
Bahlo, J.

GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY: S105

Tausch, E.; Bahlo, J.; Robrecht, S.; More

HemaSphere. 3:4, June 2019.

HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL: S106

Al-Sawaf, O.; Lilienweiss, E.; Bahlo, J.; More

HemaSphere. 3:4-5, June 2019.

FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION-FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES: S149

Fischer, K.; Al-Sawaf, O.; Bahlo, J.; More

HemaSphere. 3:26-27, June 2019.

Author:
Bahloul, Z.
Author:
Bahri, M.
Author:
Bahri, N.
Author:
Baidun, L.
Author:
Baile, M.

INTENSIVE PLAN OF THERAPEUTIC PLASMA EXCHANGE IN PATIENT WITH EXTREME HYPERTRLIGLYCERIDEMIA DUE TO L-ASPARAGINASE IN THE CONTEXT OF SMILE PROTOCOL IN T/NK NASAL LYMPHOMA TREATMENT: PF817

Sobejano, E.; López-Parra, M.; Villar, López O.; More

HemaSphere. 3:361, June 2019.

Author:
Bailén, R.
Author:
Bailey, C.
Author:
Bailey, G.
Author:
Bailey, M.
Author:
Bailey, S.
Show: